title: [Glucocorticoid-induced adverse events in patients with giant cell arteritis or polymyalgia rheumatica].
abstract: Giant cell arteritis and polymyalgia rheumatica are common reasons for prescribing long-term glucocorticoid therapy. Glucocorticoids efficacy in these patients is rapid and undeniable, but it is often overshadowed by adverse events, appearing more or less early during treatment course. These adverse events are usually minor but some of them may be life threatening. Because of the absence of randomized, controlled trials comparing glucocorticoids to placebo in this indication and in this aged population, it is difficult to precise the role of corticosteroids in the occurrence of some complications that can also be precipitated by the disease itself (e.g., vascular complications) or related to aging. In this context, analysis of the crude morbidity and mortality can help in anticipating the potential problems that these patients will encounter. In addition, the long duration of glucocorticoid exposure should prompt physicians to be particularly vigilant regarding some adverse events that are minimally symptomatic on the short term but have a major long-term impact.
authors.affiliation: Service de médecine interne, hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France. laurence.fardet@sat.aphp.fr
authors.forename: L
authors.initials: L
authors.lastname: Fardet
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D013700:Giant Cell Arteritis / Q000188:drug therapy* / Q000401:mortality; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009017:Morbidity; D011111:Polymyalgia Rheumatica / Q000188:drug therapy* / Q000401:mortality; D012307:Risk Factors
chemical_list: D005938:Glucocorticoids